Succipro

Innovation in Drug Development

Succipro is a spin-off of the CatSud Biomedical Research Institute (IRB CatSud) and the Universitat Rovira i Virgili, dedicated to developing innovative pharmaceutical solutions for the treatment of inflammatory and metabolic diseases. The team works to transform pioneering scientific discoveries into therapies that improve patients’ quality of life.

First-in-class

Leading a new era in therapeutics

Succipro develops first-in-class therapies, leading innovation in drug development to address unmet medical needs. Their research is centered around three fundamental pillars:

Succinate as a therapeutic target: A pioneering strategy that opens up extraordinary possibilities in the treatment of metabolic and inflammatory diseases.
Biomarker-based personalized therapy: The application of biomarkers to design treatments tailored to the specific needs of each patient, maximizing efficacy and minimizing variability.
Safety and efficiency: A commitment to creating medications that minimize adverse effects, always prioritizing patient safety without compromising a significant therapeutic impact.

Succipro is moving toward a novel generation of more precise, smarter treatments designed to transform patients’ lives.

Innovation and Science

We focus on cutting-edge biotechnological research for the treatment of inflammatory bowel diseases, metabolic diseases, and other associated disorders. Our technology stems from the diabetes and associated metabolic diseases research group “DIAMET”, at IRB CatSud.

Our main project focuses on the development of an innovative drug for inflammatory bowel disease.

This is a therapy based on an elegant and highly selective mechanism of action, designed to precisely modulate succinate, a key molecule in intestinal inflammation.

Thanks to this pioneering approach, we aim to offer a more effective, safer, and less invasive alternative than the treatments available today.

Follow us!

Mission

To leverage unique and world-class scientific knowledge on succinate biology to develop a new generation of therapeutic agents that precisely and selectively reduce excessive succinate levels caused by intestinal inflammation, promoting a healthy microbiome, decreasing intestinal and systemic inflammation, and preventing fibrosis. Succipro plans to advance its lead program toward early-stage clinical development for Inflammatory Bowel Disease (IBD), as well as explore additional indications in other diseases presenting elevated succinate levels, such as fatty liver associated with metabolic dysfunction.

Vision

This new generation of succinate modulation therapies opens the door to safe and effective therapeutic alternatives for patients suffering from chronic diseases with a strong inflammatory component, transforming current treatment and generating a significant positive impact on patients’ health and quality of life. A solution designed to transform the lives of these patients and mark a turning point in the management of these conditions.

Public funds

Project 101114086 funded by the WomenTechEU program
(call HORIZON-EIE-2022-SCALEUP-02; Topic HORIZON-EIE-2022-SCALEUP-02-02; Action type HORIZON-CSA)

Project ACE052/22/000049. StartUp Capital Program, with the support of ACCIÓ

PTQ2022-012572 MCIN/AEI /10.13039/501100011033

PTQ2023-012978 MCIN/AEI /10.13039/501100011033

PTQ2024-013834 MCIN/AEI /10.13039/501100011033

Project SNEO-20231359. NEOTEC 2023 Program, CDTI, Ministry of Science and Innovation, European Union – Next Generation EU.

Project CIIP-20252009, CDTI, EUROSTARS

Project CPP2024-011364, Ministry of Science, Innovation and Universities, State Research Agency, ERDF (MICIU/ AEI / 10.13039/501100011033 / ERDF, EU).

Institutional support